keyword
MENU ▼
Read by QxMD icon Read
search

Radioembolization

keyword
https://www.readbyqxmd.com/read/28934265/comparative-effectiveness-of-different-transarterial-embolization-therapies-alone-or-in-combination-with-local-ablative-or-adjuvant-systemic-treatments-for-unresectable-hepatocellular-carcinoma-a-network-meta-analysis-of-randomized-controlled-trials
#1
Konstantinos Katsanos, Panagiotis Kitrou, Stavros Spiliopoulos, Ioannis Maroulis, Theodore Petsas, Dimitris Karnabatidis
BACKGROUND: The optimal transcatheter embolization strategy for patients with unresectable hepatocellular carcinoma (HCC) remains elusive. We conducted a systematic review and network meta-analysis (NMA) of different embolization options for unresectable HCC. METHODS: Medical databases were searched for randomized controlled trials evaluating bland transarterial embolization (TAE), conventional TACE, drug-eluting bead chemoembolization (DEB-TACE), or transarterial radioembolization (TARE), either alone or combined with adjuvant chemotherapy, or local liver ablation, or external radiotherapy for unresectable HCC up to June 2017...
2017: PloS One
https://www.readbyqxmd.com/read/28916623/efficacy-of-radioembolization-with-holmium-166-microspheres-in-salvage-patients-with-liver-metastases-a-phase-2-study
#2
Jip F Prince, Maurice A A J van den Bosch, J F W Nijsen, Maarten L J Smits, Andor F van den Hoven, Stavros Nikolakopoulos, Frank J Wessels, Rutger C G Bruijnen, Manon Braat, Bernard A Zonnenberg, Marnix Lam
Rationale: Radioembolization of liver malignancies with holmium-166 (166Ho) microspheres has been shown safe in a phase 1 dose-escalation study. The purpose of this study was to investigate the efficacy of 166Ho radioembolization. Methods: In this prospective single-arm study, 56 patients were enrolled, all with liver metastases refractory to systemic therapy and ineligible for surgical resection. Radioembolization was performed with a projected average absorbed dose of 60 Gy to the liver (equal to 3.8 GBq/kg liver tissue)...
September 15, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28902765/low-dose-90y-pet-ct-imaging-optimized-for-lesion-detectability-and-quantitative-accuracy-a-phantom-study-to-assess-the-feasibility-of-pretherapy-imaging-to-plan-the-therapeutic-dose
#3
Maryam Khazaee, Alireza Kamali-Asl, Parham Geramifar, Arman Rahmim
OBJECTIVE: The overall aim of this work is to optimize the reconstruction parameters for low-dose yttrium-90 (Y) PET/computed tomography (CT) imaging, and to determine Y minimum detectable activity, in an endeavor to investigate the feasibility of performing low-dose Y imaging in-vivo to plan the therapeutic dose in radioembolization. MATERIALS AND METHODS: This study was carried out using a Siemens Biograph 6 True Point PET/CT scanner. A Jaszczak phantom containing five hot syringes was imaged serially over 15 days...
September 11, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28900709/pretransplant-intra-arterial-liver-directed-therapy-does-not-increase-the-risk-of-hepatic-arterial-complications-in-liver-transplantation-a-single-center-10-year-experience
#4
Joseph R Kallini, Ahmed Gabr, Rehan Ali, Nadine Abouchaleh, Ahsun Riaz, Talia Baker, Laura Kulik, Juan Caicedo, Riad Salem, Robert J Lewandowski
PURPOSE: To investigate the association between pretransplant intra-arterial liver-directed therapy (IAT) for hepatocellular carcinoma (HCC) and hepatic arterial complications (HAC) in orthotopic liver transplantation (OLT) [namely hepatic artery thrombosis (HAT) and/or the need for hepatic arterial conduit]. METHODS: A total of 175 HCC patients (mean age: 60 years) underwent IAT with either transarterial chemoembolization or yttrium-90 (90Y) transarterial radioembolization prior to OLT between 2003 and 2013...
September 12, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28894793/infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-treated-with-a-single-high-dose-y90-radioembolization-and-subsequent-liver-transplantation-without-a-recurrence
#5
Meaghan S Dendy, Juan C Camacho, Johannes M Ludwig, Alyssa M Krasinskas, Stuart J Knechtle, Hyun S Kim
BACKGROUND: Infiltrative hepatocellular carcinoma with macrovascular invasion is a relatively rare presentation and usually fatal disease. METHODS: Both patients exceeded Milan and University of California-San Francisco (UCSF) criteria, and per Barcelona Clinic Liver Cancer group guidelines, they were enrolled in a prospective open-label radioembolization phase II trial that gave them optimized lobar doses of Yttrium-90 as solely the first-line therapy without concomitant or additional pharmacological or locoregional therapies...
September 2017: Transplantation Direct
https://www.readbyqxmd.com/read/28890830/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-combined-with-two-stage-hepatectomy-for-multiple-and-bilobar-desmoplastic-small-round-cell-tumor-liver-metastases
#6
Alejandro Cracco, Mayank Roy, Conrad H Simpfendorfer
Desmoplastic small round cell tumor (DSRCT) is a rare mesenchymal tumor usually affecting young patients. Local dissemination is common, and liver is the most common site for extraperitoneal metastases. Multimodal management has been shown to be the most effective treatment. Some authors consider liver metastases especially bi-lobar disease as a contraindication for surgical resection. We present a case of a DSRCT with bi-lobar metastases in an adult patient who underwent multi-modal management along with hepatectomy...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28890810/updated-survival-outcomes-and-analysis-of-long-term-survivors-from-the-more-study-on-safety-and-efficacy-of-radioembolization-in-patients-with-unresectable-colorectal-cancer-liver-metastases
#7
Andrew Kennedy, Michael Cohn, Douglas M Coldwell, Alain Drooz, Eduardo Ehrenwald, Adeel Kaiser, Charles W Nutting, Steven C Rose, Eric A Wang, Michael A Savin
BACKGROUND: The Metastatic colorectal cancer liver metastases Outcomes after RadioEmbolization (MORE) study was a retrospective analysis of 606 patients with unresectable colorectal liver metastases treated with radioembolization (RE) using (90)Y-labeled resin microspheres. The first analysis of this study was completed with a last patient follow-up of 77.7 months. We now provide an updated survival analysis through September 15, 2016, with a last patient follow-up of 125 months. METHODS: (90)Y-RE was considered for patients with advanced liver-only or liver-dominant metastatic colorectal cancer which was deemed not suitable for surgery, ablation, or systemic therapy, and which had progressed or become refractory to at least one line of systemic therapy...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28890809/a-single-institute-retrospective-trial-of-concurrent-chemotherapy-with-sir-spheres-%C3%A2-versus-sir-spheres-%C3%A2-alone-in-chemotherapy-resistant-colorectal-cancer-liver-metastases
#8
May Cho, Jonathan Kessler, John J Park, Aram Lee, Jun Gong, Gagandeep Singh, Yi-Jen Chen, Philip H G Ituarte, Marwan Fakih
BACKGROUND: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIR-Spheres(®)) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres(®) with concurrent chemotherapy vs. SIR-Spheres(®) alone on liver PFS in patients with colorectal liver metastases (CRLM)...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28888827/tumor-dose-response-in-yttrium-90-resin-microsphere-embolization-for-neuroendocrine-liver-metastases-a-tumor-specific-analysis-with-dose-estimation-using-spect-ct
#9
Orapin Chansanti, Younes Jahangiri, Yusuke Matsui, Akira Adachi, Yindee Geeratikun, John A Kaufman, Kenneth J Kolbeck, Jeffrey S Stevens, Khashayar Farsad
PURPOSE: To evaluate dose-response relationship in yttrium-90 ((90)Y) resin microsphere radioembolization for neuroendocrine tumor (NET) liver metastases using a tumor-specific dose estimation based on technetium-99m-labeled macroaggregated albumin ((99m)Tc MAA) single photon emission computed tomography (SPECT)-CT. MATERIALS AND METHODS: Fifty-five tumors (mean size 3.9 cm) in 15 patients (10 women; mean age 57 y) were evaluated. Tumor-specific absorbed dose was estimated using a partition model...
September 6, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28879621/survival-analysis-of-advanced-hcc-treated-with-radioembolization-comparing-impact-of-clinical-performance-status-versus-vascular-invasion-metastases
#10
Rehan Ali, Ahmed Gabr, Nadine Abouchaleh, Ali Al Asadi, Ronald A Mora, Laura Kulik, Michael Abecassis, Ahsun Riaz, Riad Salem, Robert J Lewandowski
PURPOSE: In this study, we aim to compare the effects of prognostic indicators on survival analysis for Barcelona Clinic Liver Cancer (BCLC) C patients undergoing yttrium-90 radioembolization (Y-90). METHODS: A prospectively acquired database (2003-2017) for BCLC C hepatocellular carcinoma (HCC) patients that underwent radioembolization with Y-90 was searched. The criteria for BCLC C status (Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or 2, metastases, and/or portal vein thrombosis (PVT)) were recorded...
September 6, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28875374/yttrium-90-radioembolization-treatment-for-unresectable-hepatocellular-carcinoma-a-single-centre-prognostic-factors-analysis
#11
C Floridi, F Pesapane, S A Angileri, D De Palma, F Fontana, F Caspani, A Barile, A Del Sole, C Masciocchi, G Lucignani, G Carrafiello
The aim of this study was to evaluate the efficacy and the safety of Y90 radioembolization (Y90-RE) in patients with unresectable hepatocellular carcinoma (HCC) analysing our results and correlating them with independent prognostic factors for overall survival (OS) and for complications. Forty-three patients with advanced inoperable HCC including those with multiple bilobar lesions or portal vein thrombosis (PVT) treated with Y90-RE were reviewed. Treatment efficacy and safety were evaluated. Survival was calculated by the Kaplan-Meier method...
September 5, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28871990/transarterial-radioembolization-versus-concurrent-chemoradiation-therapy-for-locally-advanced-hepatocellular-carcinoma-a%C3%A2-propensity-score-matching-analysis
#12
Jeong Eun Song, Kyu Sik Jung, Do Young Kim, Kijun Song, Jong Yun Won, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han
PURPOSE: It is unclear whether the efficacy and safety of concurrent chemoradiation therapy (CCRT) and transarterial radioembolization (TARE) with (90)Y are comparable in patients with locally advanced hepatocellular carcinoma. METHODS AND MATERIALS: In total, 209 treatment-naive patients with stage B or C cancer according to the Barcelona Clinic Liver Cancer classification who were treated with TARE or CCRT were analyzed. Propensity scores were calculated and matched at a 1:1 ratio for TARE versus CCRT using age, tumor size, tumor number, portal vein thrombosis, and Barcelona Clinic Liver Cancer staging...
October 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28868022/successful-yttrium-90-microsphere-radioembolization-for-hepatic-metastases-of-prostate-cancer
#13
Alexander C Bunck, Daniel Pinto Dos Santos, De-Hua Chang, Marcel Reiser, David Pfister, Anne Bunck, Alexander Drzezga, David Maintz, Matthias Schmidt
Prostate cancer is the most common solid tumor malignancy worldwide with an estimated 180,000 new cases of prostate cancer and 26,000 deaths in the USA in 2016. Although significant advances in the treatment of prostate cancer have recently been made, the treatment of metastatic disease remains a challenge. With visceral metastases marking more advanced tumor stages, liver involvement is associated with the worst prognosis. So far, no locoregional treatment regimens for the management of liver metastases of prostatic cancer exist...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28864605/radioembolization-of-colorectal-liver-metastases-indications-technique-and-outcomes
#14
F Edward Boas, Lisa Bodei, Constantinos T Sofocleous
Liver metastases are a major cause of death from colorectal cancer. Intraarterial therapy options for colorectal liver metastases include chemoinfusion via a hepatic arterial pump or port, irinotecan-loaded drug-eluting beads, and radioembolization using (90)Y microspheres. Intraarterial therapy allows the delivery of a high dose of chemotherapy or radiation into liver tumors while minimizing the impact on liver parenchyma and avoiding systemic effects. Specificity in intraarterial therapy can be achieved both through preferential arterial flow to the tumor and through selective catheter positioning...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28852599/impressive-response-to-concomitant-platinum-based-chemotherapy-and-yttrium-90-in-a-patient-with-heavily-pretreated-triple-negative-breast-cancer-widely-metastasized-to-the-liver
#15
Aurelio Castrellon, Steven M Nguyen, Federico Bengoa, Ana Botero, Luis E Raez
Metastatic triple-negative breast cancer (TNBC) constitutes a heterogeneous group of diseases with systemic treatment options limited to cytotoxic chemotherapy at the time being. The disease tends to affect visceral organs more frequently when compared to hormone receptor-positive breast cancer. The prognoses of patients with heavily pretreated disease affecting the liver are very dismal. We present the response to radioembolization and systemic chemotherapy in a seriously ill patient who had undergone previous lines of chemotherapy for TNBC with extensive liver metastases...
June 28, 2017: Curēus
https://www.readbyqxmd.com/read/28836737/hepatic-artery-and-biliary-complications-in-liver-transplant-recipients-with-radioembolization-bridging-treatment-for-hepatocellular-carcinoma
#16
Sonia Radunz, Fuat H Saner, Jürgen Treckmann, Jan Rekowski, Jens M Theysohn, Stefan Müller, Jan Best, Georgios C Sotiropoulos, Andreas Paul, Tamás Benkö
BACKGROUND: Locoregional bridging treatments are commonly applied in hepatocellular carcinoma (HCC) patients prior to liver transplantation to prevent tumor progression during waiting time. It remains unknown whether pre-transplant radioembolization treatment may increase the prevalence of hepatic artery and biliary complications post-transplant. METHODS: We performed a retrospective review of 173 consecutive HCC patients who underwent liver transplantation at our transplant center between January 2007 and December 2016...
August 24, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28834778/outcomes-of-radioembolization-for-unresectable-hepatocellular-carcinoma-in-patients-with-marginal-functional-hepatic-reserve
#17
Derek M Biederman, Raghuram Posham, Raisa J Durrani, Joseph J Titano, Rahul S Patel, Nora E Tabori, Francis S Nowakowski, Aaron M Fischman, Robert A Lookstein, Edward Kim
PURPOSE: To evaluate the outcomes of radioembolization (RE) as a therapy for unresectable hepatocellular carcinoma (HCC) in patients with marginal functional hepatic reserve. METHODS: A retrospective review of 471 patients (1/2010-7/2015) treated with RE (Therasphere, BTG, UK) was performed. A total of 36 patients (mean age: 66.1±9.3, male: 86.1%) underwent therapy for HCC with a MELD≥15 (median: 16, range: 15-22). Baseline demographics of the study cohort were as follows: etiology (HCV: 26, 72...
July 20, 2017: Clinical Imaging
https://www.readbyqxmd.com/read/28833344/radioembolization-for-hepatocellular-carcinoma-statistical-confirmation-of-improved-survival-in-responders-by-landmark-analyses
#18
Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ali Alasadi, Ronald Mora, Laura Kulik, Kush Desai, Bartley Thornburg, Samdeep Mouli, Ryan Hickey, Frank H Miller, Vahid Yaghmai, Daniel Ganger, Robert J Lewandowski, Riad Salem
Does imaging response predict survival in hepatocellular carcinoma (HCC)? We studied the ability of post-therapeutic imaging response to predict overall survival. Over 14 years, 948 HCC patients were treated with radioembolization. Patients with baseline metastases, vascular invasion, multifocal disease, Child-Pugh>B7 and transplanted/resected were excluded. This created our homogenous study cohort of 134 Child-Pugh≤B7 patients with solitary HCC. Response (using European Association for Study of the Liver [EASL] and Response Evaluation Criteria in Solid Tumors 1...
August 18, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28828119/coil-embolization-of-reversed-curve-hepatointestinal-collaterals-in-radioembolization-potential-solutions-for-a-challenging-task
#19
Jan B Hinrichs, Steffen Marquardt, Frank K Wacker, Bernhard C Meyer
Depending on the planned catheter position for selective internal radioembolization, coil embolization of hepatic artery branches can be necessary to enable a selective and safe procedure. The anatomy of the hepatic arterial bed has been demonstrated to have a substantial number of anatomic variations, which turns coil embolization into a challenge if the feeder shows a reversed, "hairpin-like" turn immediately after its origin. Hepatointestinal collateral vessels originating from the periphery of the right hepatic artery often present with such a reversed course and can preclude patients from uncomplicated radioembolization if catheterization fails...
September 2017: Radiology case reports
https://www.readbyqxmd.com/read/28818953/new-horizons-for-precision-medicine-in-biliary-tract-cancers
#20
REVIEW
Juan W Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X Zhu
Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-prognosis and low-incidence cancers, although the incidence of intrahepatic cholangiocarcinoma is rising. A minority of patients present with resectable disease but relapse rates are high; benefit from adjuvant capecitabine chemotherapy has been demonstrated. Cisplatin/gemcitabine combination chemotherapy has emerged as the reference first-line treatment regimen; there is no standard second-line therapy. Selected patients may be suitable for liver-directed therapy (e...
September 2017: Cancer Discovery
keyword
keyword
13605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"